These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25288146)

  • 1. Persistent drug interaction between aprepitant and warfarin in patients receiving anticancer chemotherapy.
    Ohno Y; Yamada M; Yamaguchi R; Hisaka A; Suzuki H
    Int J Clin Pharm; 2014 Dec; 36(6):1134-7. PubMed ID: 25288146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Drug-Drug Interaction between Warfarin and Aprepitant and Its Effects on PT-INR of Patients Receiving Anticancer Chemotherapy.
    Takaki J; Ohno Y; Yamada M; Yamaguchi R; Hisaka A; Suzuki H
    Biol Pharm Bull; 2016 May; 39(5):863-8. PubMed ID: 26948084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient elevation of international normalized ratio during cisplatin-based chemotherapy in patients who are taking warfarin.
    Yano R; Kurokawa T; Tsuyoshi H; Shinagawa A; Sawamura Y; Matsunaga A; Nakamura T; Yoshida Y; Yoneda M; Kotsuji F; Masada M
    Ann Pharmacother; 2011 Oct; 45(10):e55. PubMed ID: 21881031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin.
    Depré M; Van Hecken A; Oeyen M; De Lepeleire I; Laethem T; Rothenberg P; Petty KJ; Majumdar A; Crumley T; Panebianco D; Bergman A; de Hoon JN
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):341-6. PubMed ID: 15983826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide and etoposide chemotherapy may interact with warfarin, enhancing the warfarin induced anticoagulant response.
    Okada N; Watanabe H; Kagami S; Ishizawa K
    Int J Clin Pharmacol Ther; 2016 Jan; 54(1):58-61. PubMed ID: 26587904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin.
    Peterson D; Van Ermen A
    Am J Health Syst Pharm; 2017 Jun; 74(12):888-892. PubMed ID: 28596225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
    Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
    Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails.
    Hu W; Fang J; Nie J; Dai L; Chen X; Zhang J; Ma X; Tian G; Han J
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1129-36. PubMed ID: 24748417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-Fluorouracil therapy.
    Davis DA; Fugate SE
    Pharmacotherapy; 2005 Mar; 25(3):442-7. PubMed ID: 15843293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin.
    Choi CH; Kim MK; Park JY; Yoon A; Kim HJ; Lee YY; Kim TJ; Lee JW; Kim BG; Bae DS
    Support Care Cancer; 2014 May; 22(5):1181-7. PubMed ID: 24337621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.
    Llombart-Cussac A; Ramos M; Dalmau E; García-Saenz JA; González-Farré X; Murillo L; Calvo L; Morales S; Carañana V; González A; Fernández-Morales LA; Moreno F; Casas MI; Angulo Mdel M; Cámara MC; Garcia-Mace AI; Carrasco E; Jara-Sánchez C
    Eur J Cancer; 2016 May; 58():122-9. PubMed ID: 26994459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible contribution of aprepitant to ifosfamide-induced neurotoxicity.
    Jarkowski A
    Am J Health Syst Pharm; 2008 Dec; 65(23):2229-31. PubMed ID: 19020190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
    Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
    J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
    Kim JE; Jang JS; Kim JW; Sung YL; Cho CH; Lee MA; Kim DJ; Ahn MJ; Lee KY; Sym SJ; Lim MC; Jung H; Cho EK; Min KW
    Support Care Cancer; 2017 Mar; 25(3):801-809. PubMed ID: 27826874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated International Normalized Ratio values in a patient receiving warfarin and ceftaroline.
    Farhat NM; Hutchinson LS; Peters M
    Am J Health Syst Pharm; 2016 Jan; 73(2):56-9. PubMed ID: 26721534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy.
    Abdel-Malek R; Abbas N; Shohdy KS; Ismail M; Fawzy R; Salem DS; Safwat E
    J Egypt Natl Canc Inst; 2017 Sep; 29(3):155-158. PubMed ID: 28844591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV).
    Choi MR; Jiles C; Seibel NL
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):e268-71. PubMed ID: 20736848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database.
    Knudsen JF; Sokol GH
    Pharmacotherapy; 2008 Apr; 28(4):540-8. PubMed ID: 18363538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated international normalized ratio associated with concomitant warfarin and erlotinib.
    Thomas KS; Billingsley A; Amarshi N; Nair BA
    Am J Health Syst Pharm; 2010 Sep; 67(17):1426-9. PubMed ID: 20720241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.